Lipid metabolites in the pathogenesis and treatment of neovascular eye disease

British Journal of Ophthalmology

Volumn 95, Issue 11, 2011, Pages 1496-1501

  Stahl, Andreas ^a,b   Krohne, Tim U ^c   Sapieha, Przemyslaw ^d   Chen, Jing ^a   Hellstrom, Ann ^e   Chew, Emily ^f   Holz, Frank G ^c   Smith, Lois E H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 5 HYDROXYICOSATETRAENOIC ACID; ANGIOPOIETIN 2; ARACHIDONIC ACID; AUTOTAXIN; CYCLOOXYGENASE 2; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; FENOFIBRATE; GELATINASE B; LIPID; LIPOXYGENASE; MALONALDEHYDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; ROSIGLITAZONE; VASCULOTROPIN;

ANGIOGENESIS; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME STRUCTURE; EXUDATIVE MACULAR DEGENERATION; EYE DISEASE; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION;

DIABETIC RETINOPATHY; EYE; FATTY ACIDS, UNSATURATED; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LIPID METABOLISM; LIPID PEROXIDATION; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; RETINOPATHY OF PREMATURITY;

EID: 80054891241     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.194241     Document Type: Review

References (91)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977;195:880-2. (Pubitemid 8048148)
3. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
4. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-18. (Pubitemid 38868391)
5. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. (Pubitemid 350100775)
6. Bartoli M, Al-Shabrawey M, Labazi M, et al. HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2009;50:4934-40.
7. Sangiovanni JP, Agron E, Meleth AD, et al. ω3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr 2009;90:1601-7.
8. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol 2007;125:671-9. (Pubitemid 46762729)
9. Krohne TU, Stratmann NK, Kopitz J, et al. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 2010;90:465-71.
10. Tuo J, Ross RJ, Herzlich AA, et al. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol 2009;175:799-807.
11. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868-73. (Pubitemid 47038185)
12. Tang Y, Scheef EA, Wang S, et al. CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood 2009;113:744-54.
13. Weinberger B, Nisar S, Anwar M, et al. Lipid peroxidation in cord blood and neonatal outcome. Pediatr Int 2006;48:479-83. (Pubitemid 44386573)
14. Leduc M, Kermorvant-Duchemin E, Checchin D, et al. Hypercapnia- and transarachidonic acid-induced retinal microvascular degeneration: implications in the genesis of retinopathy of prematurity. Semin Perinatol 2006;30:129-38. (Pubitemid 43928132)
15. Sheets KG, Zhou Y, Ertel MK, et al. Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse. Mol Vis 2010;16:320-9.
16. Stahl A, Sapieha P, Connor KM, et al. PPARγ mediates a direct antiangiogenic effect of ω3-PUFAs in proliferative retinopathy. Circ Res 2010;107:476-84.
17. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005;24:87-138. (Pubitemid 39535157)
18. Tan JS, Wang JJ, Flood V, et al. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2009;127:656-65.
19. Good WV, Hardy RJ. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology 2001;108:1013-14. (Pubitemid 32500013)
20. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-83. (Pubitemid 47493723)
21. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85. (Pubitemid 38456282)
22. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614. (Pubitemid 38456297)
23. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol 2004;242:710-16. (Pubitemid 39242849)
24. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-34.
25. Kopitz J, Holz FG, Kaemmerer E, et al. Lipids and lipid peroxidation products in the pathogenesis of age-related macular degeneration. Biochimie 2004;86:825-31. (Pubitemid 39602762)
26. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128. (Pubitemid 121003917)
27. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278:42027-35. (Pubitemid 37310467)
28. Kapphahn RJ, Giwa BM, Berg KM, et al. Retinal proteins modified by 4-hydroxynonenal: identification of molecular targets. Exp Eye Res 2006;83:165-75. (Pubitemid 44208739)
29. Tanito M, Elliott MH, Kotake Y, et al. Protein modifications by 4-hydroxynonenal and 4-hydroxyhexenal in light-exposed rat retina. Invest Ophthalmol Vis Sci 2005;46:3859-68. (Pubitemid 44264698)
30. Spaide RF, Ho-Spaide WC, Browne RW, et al. Characterization of peroxidized lipids in Bruch's membrane. Retina 1999;19:141-7. (Pubitemid 30368160)
31. Schutt F, Bergmann M, Holz FG, et al. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003;44:3663-8. (Pubitemid 36909809)
32. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 2002;99:14682-7. (Pubitemid 35334544)
33. Kaemmerer E, Schutt F, Krohne TU, et al. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis. Invest Ophthalmol Vis Sci 2007;48:1342-7. (Pubitemid 351261433)
34. Krohne TU, Kaemmerer E, Holz FG, et al. Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action. Exp Eye Res 2010;90:261-6.
35. Krohne TU, Holz FG, Kopitz J. Apical-to-basolateral transcytosis of photoreceptor outer segments induced by lipid peroxidation products in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010;51:553-60.
36. Ebrahem Q, Renganathan K, Sears J, et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: implications for age-related macular degeneration. Proc Natl Acad Sci U S A 2006;103:13480-4. (Pubitemid 44380133)
37. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 2008; 14:194-8. (Pubitemid 351214555)
38. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
39. Negre-Salvayre A, Coatrieux C, Ingueneau C, et al. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008;153:6-20.
40. Kesavulu MM, Giri R, Kameswara Rao B, et al. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Metab 2000;26:387-92.
41. Winterbourn CC, Chan T, Buss IH, et al. Protein carbonyls and lipid peroxidation products as oxidation markers in preterm infant plasma: associations with chronic lung disease and retinopathy and effects of selenium supplementation. Pediatr Res 2000;48:84-90. (Pubitemid 30419175)
42. Verdejo C, Marco P, Renau-Piqueras J, et al. Lipid peroxidation in proliferative vitreoretinopathies. Eye (Lond) 1999;13:183-8. (Pubitemid 29210137)
43. Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005;11:1339-45. (Pubitemid 41752915)
44. Pazdro R, Burgess JR. The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev 2010;131:276-86.
45. Lee CT, Gayton EL, Beulens JW, et al. Micronutrients and diabetic retinopathy a systematic review. Ophthalmology 2010;117:71-8.
46. Johnson EJ. Age-related macular degeneration and antioxidant vitamins: recent findings. Curr Opin Clin Nutr Metab Care 2010;13:28-33.
47. Hardy P, Beauchamp M, Sennlaub F, et al. Inflammatory lipid mediators in ischemic retinopathy. Pharmacol Rep 2005;(Suppl 57):169-90.
48. Lin CI, Chen CN, Huang MT, et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms. Cell Signal 2008;20:1804-14.
49. Bazan NG. Free arachidonic acid and other lipids in the nervous system during early ischemia and after electroshock. Adv Exp Med Biol 1976;72:317-35.
50. Phillis JW, O'Regan MH. A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 2004;44:13-47. (Pubitemid 38114757)
51. Bonventre JV. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity. J Lipid Mediat Cell Signal 1996;14:15-23. (Pubitemid 26343332)
52. Matsuo Y, Kihara T, Ikeda M, et al. Role of platelet-activating factor and thromboxane A2 in radical production during ischemia and reperfusion of the rat brain. Brain Res 1996;709:296-302. (Pubitemid 26071273)
53. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003;108:198-204. (Pubitemid 36871303)
54. Beauchamp MH, Martinez-Bermudez AK, Gobeil F Jr, et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol 2001;90:2279-88. (Pubitemid 32467422)
55. Stevens MK, Yaksh TL. Time course of release in vivo of PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 into the brain extracellular space after 15 min of complete global ischemia in the presence and absence of cyclooxygenase inhibition. J Cereb Blood Flow Metab 1988;8:790-8. (Pubitemid 19008322)
56. Flower RW, McLeod DS, Wajer SD, et al. Prostaglandins as mediators of vasotonia in the immature retina. Pediatrics 1984;73:440-4. (Pubitemid 14131471)
57. Zhu Y, Park TS, Gidday JM. Mechanisms of hyperoxia-induced reductions in retinal blood flow in newborn pig. Exp Eye Res 1998;67:357-69. (Pubitemid 28483235)
58. Barnett JM, McCollum GW, Penn JS. Role of cytosolic phospholipase A(2) in retinal neovascularization. Invest Ophthalmol Vis Sci 2010;51:1136-42.
59. Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008;111:3514-21.
60. Schwartzman ML, Iserovich P, Gotlinger K, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes 2010;59:1780-8.
61. Zeng ZZ, Yellaturu CR, Neeli I, et al. 5(S)-Hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2. J Biol Chem 2002;277:41213-19. (Pubitemid 35215713)
62. Michaelis UR, Fisslthaler B, Medhora M, et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 2003;17:770-2.
63. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 2010;459:881-95.
64. Jenkins AJ, Rowley KG, Lyons TJ, et al. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004;10:3395-418. (Pubitemid 39276625)
65. Ferris FL 3rd, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 1996;19:1291-3.
66. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
67. Ucgun NI, Yildirim Z, Kilic N, et al. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 2007;1100:213-17. (Pubitemid 47092655)
68. Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of the novel antiinflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 2009;50:4743-52.
69. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61. (Pubitemid 351595216)
70. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-37. (Pubitemid 35231761)
71. Calandria JM, Bazan NG. Neuroprotectin D1 modulates the induction of pro-inflammatory signaling and promotes retinal pigment epithelial cell survival during oxidative stress. Adv Exp Med Biol 2010;664:663-70.
72. Calandria JM, Marcheselli VL, Mukherjee PK, et al. Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem 2009;284:17877-82.
73. Le HD, Meisel JA, de Meijer VE, et al. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 2009;81:165-70.
74. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000;107:2224-32.
75. Cai J, Nelson KC, Wu M, et al. Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205-21.
76. Stahl A, Paschek L, Martin G, et al. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009;247:767-73.
77. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-40. (Pubitemid 46440629)
78. Jones M. Effect of preterm birth on airway function and lung growth. Paediatr Respir Rev 2009;(10 Suppl 1):9-11.
79. Shen LQ, Child A, Weber GM, et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 2008;126:793-9. (Pubitemid 351831328)
80. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997;11:779-91. (Pubitemid 27225305)
81. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 2009;4:1565-73.
82. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 2010;51:2813-26.
83. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-11. (Pubitemid 24046832)
84. Stahl A, Connor KM, Sapieha P, et al. Computer-aided quantification of retinal neovascularization. Angiogenesis 2009;12:297-301.
85. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-61.
86. Lapillonne A, Jensen CL. Reevaluation of the DHA requirement for the premature infant. Prostaglandins Leukot Essent Fatty Acids 2009;81:143-50.
87. Cheung HM, Lam HS, Tam YH, et al. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin Nutr 2009;28:209-12.
88. de Meijer VE, Gura KM, Le HD, et al. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr 2009;33:541-7.
89. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina 2010;30:459-67.
90. Christen WG, Glynn RJ, Chew EY, et al. Low-dose aspirin and medical recordconfirmed age-related macular degeneration in a randomized trial of women. Ophthalmology 2009;116:2386-92.
91. de Jong PT. Aspirin and age-related macular degeneration. Ophthalmology 2010;117:1279-80; author reply 1280.